Correlation Between Hepion Pharmaceuticals and ZyVersa Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Hepion Pharmaceuticals and ZyVersa Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hepion Pharmaceuticals and ZyVersa Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Hepion Pharmaceuticals and ZyVersa Therapeutics, you can compare the effects of market volatilities on Hepion Pharmaceuticals and ZyVersa Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hepion Pharmaceuticals with a short position of ZyVersa Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hepion Pharmaceuticals and ZyVersa Therapeutics.

Diversification Opportunities for Hepion Pharmaceuticals and ZyVersa Therapeutics

0.7
  Correlation Coefficient

Poor diversification

The 3 months correlation between Hepion and ZyVersa is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Hepion Pharmaceuticals and ZyVersa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ZyVersa Therapeutics and Hepion Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hepion Pharmaceuticals are associated (or correlated) with ZyVersa Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ZyVersa Therapeutics has no effect on the direction of Hepion Pharmaceuticals i.e., Hepion Pharmaceuticals and ZyVersa Therapeutics go up and down completely randomly.

Pair Corralation between Hepion Pharmaceuticals and ZyVersa Therapeutics

Given the investment horizon of 90 days Hepion Pharmaceuticals is expected to generate 0.94 times more return on investment than ZyVersa Therapeutics. However, Hepion Pharmaceuticals is 1.07 times less risky than ZyVersa Therapeutics. It trades about -0.06 of its potential returns per unit of risk. ZyVersa Therapeutics is currently generating about -0.11 per unit of risk. If you would invest  1,452  in Hepion Pharmaceuticals on June 26, 2024 and sell it today you would lose (1,381) from holding Hepion Pharmaceuticals or give up 95.11% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Hepion Pharmaceuticals  vs.  ZyVersa Therapeutics

 Performance 
       Timeline  
Hepion Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Hepion Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in October 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
ZyVersa Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ZyVersa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in October 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Hepion Pharmaceuticals and ZyVersa Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Hepion Pharmaceuticals and ZyVersa Therapeutics

The main advantage of trading using opposite Hepion Pharmaceuticals and ZyVersa Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hepion Pharmaceuticals position performs unexpectedly, ZyVersa Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ZyVersa Therapeutics will offset losses from the drop in ZyVersa Therapeutics' long position.
The idea behind Hepion Pharmaceuticals and ZyVersa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Other Complementary Tools

Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets